Dyne Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Good morning and welcome to day two of Guggenheim's Genomic Medicines and Rare Disease Conference. This is our fifth iteration. My name is Debjit, and I'm one of the therapeutic analysts at Guggenheim; my privilege to host Wildon Farwell, CMO; and Jonathan McNeill, SVP of Business Development from Dyne Therapeutics. I'm not sure if Amy is on the call as well, but if Amy is on, Amy Reilly, Head of Corporate Communications and IR is on as well.
Questions & Answers
Given the limited time, let's get straight to it on the thoughts on the FORCE platform and how the technology differentiates itself versus non-specific approaches in neuromuscular diseases?
Yeah, thanks Debjit, thanks for the opportunity to join you today. Before we start, I just want to remind everyone that we'll be making forward-looking statements, so please
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |